Sildenafil Citrate Tablet, Film Coated
Product Images NDC 68071-3410

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Sildenafil Citrate (NDC 68071-3410). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3410 3)

Label for Sildenafil 100 mg tablets by NuCare Pharmaceuticals, Inc. The label indicates a prescription drug in tablet form with a quantity of 30 tablets. The label includes manufacturer and packaging details with warnings to keep out of reach of children and storage instructions at controlled temperature 68-77°F. Barcode, lot, expiration, and serial number fields are printed but filled with placeholder zeros.*

FDA Label Image

Sildenafil_fig1.jpg (Sildenafil Fig1)

A line graph depicting the mean change from baseline in sitting systolic blood pressure over 24 hours in healthy volunteers. The x-axis shows time post dose in hours, and the y-axis shows systolic blood pressure change in mmHg. Two lines represent Sildenafil 100 mg and placebo groups.*

FDA Label Image

Sildenafil_fig3 (Sildenafil Fig 3)

A line graph depicting the mean standing systolic blood pressure changes from baseline over an eight-hour period following dosing. The graph compares two groups: Doxazosin with placebo and Doxazosin with Sildenafil 50 mg. Time postdose in hours is plotted on the x-axis, and systolic blood pressure change in mm Hg is on the y-axis.*

FDA Label Image

Sildenafil_fig_4 (Sildenafil Fig 4)

A line graph showing mean standing systolic blood pressure change from baseline over an 8-hour period after dosing. The graph compares two groups: one receiving Doxazosin plus Sildenafil 100 mg and the other receiving Doxazosin plus placebo, with blood pressure changes plotted in mmHg on the vertical axis and time after dosing in hours on the horizontal axis.*

FDA Label Image

Sidenafil_fig_5 (Sildenafil Fig 5)

A line graph displaying mean plasma concentrations of Sildenafil over time in healthy male volunteers. The x-axis represents time post dose in hours, ranging from 0 to 24 hours, and the y-axis shows plasma concentrations in ng/ml. Data points indicate measurements after administration of a commercial tablet form of Sildenafil.*

FDA Label Image

Sildenafil-fig7 (Sildenafil Fig7)

A bar graph showing the percentage of patients reporting improvement across different treatment groups. The x-axis lists treatment groups: Placebo (n=463), Sildenafil Tablets 25 mg (n=214), Sildenafil Tablets 50 mg (n=391), and Sildenafil Tablets 100 mg (n=380). The y-axis shows percentages from 0 to 100%. Reported improvement percentages increase from Placebo at 24% to Sildenafil 100 mg tablets at 82%.*

FDA Label Image

Str (Sildenafil Structure)

Chemical structure of Sildenafil, the active ingredient in Sildenafil Citrate 100 mg film-coated tablets by NuCare Pharmaceuticals, Inc. The diagram shows the molecular arrangement including rings and functional groups.*

FDA Label Image

Figure2 (Sildenafil Fig2)

A line graph showing change in blood pressure (DBP in mmHG) over time (hours) comparing Doxazosin with Placebo and Doxazosin with Sildenafil 25 mg. The x-axis represents time postdose in hours, and the y-axis represents change in DBP. Two lines plot the data for each treatment group across the 8-hour timeframe.*

FDA Label Image

Sildenafil_fig6b (Sildenafil Fig6b)

A bar chart showing the percentage of patients at endpoint categorized by baseline score. The x-axis represents baseline scores from 0 to 5, and the y-axis represents the percentage of patients. Multiple bars per category indicate different groups or conditions compared across the baseline scores.*

FDA Label Image

Sildenafil_fig6a (Sildenafil Figure6a)

Bar chart displaying the percentage of patients at endpoint across different baseline scores for a clinical measure. The chart includes multiple series represented by different colors or patterns as indicated in the legend on the right, with baseline scores ranging from 0 to 5 on the x-axis and percentage of patients on the y-axis.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.